207 related articles for article (PubMed ID: 30810839)
61. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis.
Sumiyoshi S; Yoshizawa A; Sonobe M; Kobayashi M; Sato M; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Jun; 84(3):281-8. PubMed ID: 24725383
[TBL] [Abstract][Full Text] [Related]
62. Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures.
Deng H; Liu C; Zhang G; Wang X; Liu Y
Pathol Res Pract; 2018 Dec; 214(12):2103-2105. PubMed ID: 30327151
[TBL] [Abstract][Full Text] [Related]
63. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
64. [To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung].
Sun PL; Liu JN; Cao LQ; Yao M; Gao HW
Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):303-308. PubMed ID: 28468034
[No Abstract] [Full Text] [Related]
65. USP7 overexpression predicts a poor prognosis in lung squamous cell carcinoma and large cell carcinoma.
Zhao GY; Lin ZW; Lu CL; Gu J; Yuan YF; Xu FK; Liu RH; Ge D; Ding JY
Tumour Biol; 2015 Mar; 36(3):1721-9. PubMed ID: 25519684
[TBL] [Abstract][Full Text] [Related]
66. [Study on the Difference of Gene Expression between Central and Peripheral Lung Squamous Cell Carcinoma Based on TCGA Database].
Li W; Li Y; Zhang H; Li Y; Yuan Y; Gong H; Wei S; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):280-288. PubMed ID: 31109437
[TBL] [Abstract][Full Text] [Related]
67. Association of specific gene mutations derived from machine learning with survival in lung adenocarcinoma.
Cho HJ; Lee S; Ji YG; Lee DH
PLoS One; 2018; 13(11):e0207204. PubMed ID: 30419062
[TBL] [Abstract][Full Text] [Related]
68. Expression profiling of ubiquitin-related genes in LKB1 mutant lung adenocarcinoma.
Wang G; Bie F; Qu X; Yang X; Liu S; Wang Y; Huang C; Wang K; Du J
Sci Rep; 2018 Sep; 8(1):13221. PubMed ID: 30185829
[TBL] [Abstract][Full Text] [Related]
69. Prognostic value of aberrantly expressed methylation gene profiles in lung squamous cell carcinoma: A study based on The Cancer Genome Atlas.
Gao C; Zhuang J; Zhou C; Ma K; Zhao M; Liu C; Liu L; Li H; Feng F; Sun C
J Cell Physiol; 2019 May; 234(5):6519-6528. PubMed ID: 30246311
[TBL] [Abstract][Full Text] [Related]
70. Spatial whole exome sequencing reveals the genetic features of highly-aggressive components in lung adenocarcinoma.
Li J; Xiong S; He P; Liang P; Li C; Zhong R; Cai X; Xie Z; Liu J; Cheng B; Chen Z; Liang H; Lao S; Chen Z; Shi J; Li F; Feng Y; Huo Z; Deng H; Yu Z; Wang H; Zhan S; Xiang Y; Wang H; Zheng Y; Lin X; He J; Liang W
Neoplasia; 2024 Aug; 54():101013. PubMed ID: 38850835
[TBL] [Abstract][Full Text] [Related]
71. Development of somatic mutation signatures for risk stratification and prognosis in lung and colorectal adenocarcinomas.
Menor M; Zhu Y; Wang Y; Zhang J; Jiang B; Deng Y
BMC Med Genomics; 2019 Jan; 12(Suppl 1):24. PubMed ID: 30704450
[TBL] [Abstract][Full Text] [Related]
72. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung.
Malanga D; Scrima M; De Marco C; Fabiani F; De Rosa N; De Gisi S; Malara N; Savino R; Rocco G; Chiappetta G; Franco R; Tirino V; Pirozzi G; Viglietto G
Cell Cycle; 2008 Mar; 7(5):665-9. PubMed ID: 18256540
[TBL] [Abstract][Full Text] [Related]
73. Comprehensive genomic and prognostic analysis of the IL‑17 family genes in lung cancer.
Liao T; Fan J; Lv Z; Xu J; Wu F; Yang G; Huang Q; Guo M; Hu G; Zhou M; Duan L; Wang S; Jin Y
Mol Med Rep; 2019 Jun; 19(6):4906-4918. PubMed ID: 31059089
[TBL] [Abstract][Full Text] [Related]
74. Research on circadian clock genes in non-small-cell lung carcinoma.
Qiu M; Chen YB; Jin S; Fang XF; He XX; Xiong ZF; Yang SL
Chronobiol Int; 2019 Jun; 36(6):739-750. PubMed ID: 31014124
[TBL] [Abstract][Full Text] [Related]
75. Genome-scale analysis to identify prognostic markers and predict the survival of lung adenocarcinoma.
Li YY; Yang C; Zhou P; Zhang S; Yao Y; Li D
J Cell Biochem; 2018 Nov; 119(11):8909-8921. PubMed ID: 30105759
[TBL] [Abstract][Full Text] [Related]
76. Systematic Inspection of the Clinical Relevance of TP53 Missense Mutations in Gastric Cancer.
Moon S; Balch C; Park S; Lee J; Sung J; Nam S
IEEE/ACM Trans Comput Biol Bioinform; 2019; 16(5):1693-1701. PubMed ID: 29994072
[TBL] [Abstract][Full Text] [Related]
77. Somatic genome alterations in relation to age in lung adenocarcinoma.
Meucci S; Keilholz U; Heim D; Klauschen F; Cacciatore S
Int J Cancer; 2019 Oct; 145(8):2091-2099. PubMed ID: 30859574
[TBL] [Abstract][Full Text] [Related]
78. LUADpp: an effective prediction model on prognosis of lung adenocarcinomas based on somatic mutational features.
Yu J; Hu Y; Xu Y; Wang J; Kuang J; Zhang W; Shao J; Guo D; Wang Y
BMC Cancer; 2019 Mar; 19(1):263. PubMed ID: 30902072
[TBL] [Abstract][Full Text] [Related]
79. Smoking, lung cancers and their TP53 mutations.
Cooper CS
Mutagenesis; 2002 Jul; 17(4):279-80. PubMed ID: 12110621
[No Abstract] [Full Text] [Related]
80. Genomic landscape of squamous cell carcinoma of the lung.
Morgensztern D; Devarakonda S; Govindan R
Am Soc Clin Oncol Educ Book; 2013; ():348-53. PubMed ID: 23714544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
